Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Epistemonikos ID: e0a1ac492f05cdb6d1d94d3422f02df29e1908a0
First added on: May 21, 2024